Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Physiomics ( (GB:PYC) ) has issued an announcement.
Physiomics plc has announced the publication of a peer-reviewed article in collaboration with Ankyra Therapeutics, detailing a pharmacokinetic and pharmacodynamic model for an interleukin-12 anchored-drug conjugate aimed at treating solid tumors. This publication highlights the growing importance of mathematical modelling in drug development, showcasing Physiomics’ capability to support successful drug development programs and its strong positioning in the market amid increasing regulatory pressures.
Spark’s Take on GB:PYC Stock
According to Spark, TipRanks’ AI Analyst, GB:PYC is a Underperform.
Physiomics faces substantial financial and technical challenges, reflected in declining revenues and bearish technical indicators. Recent corporate events provide some optimism for future growth, but current valuation issues and financial instability weigh heavily on its stock score.
To see Spark’s full report on GB:PYC stock, click here.
More about Physiomics
Physiomics plc is a leader in mathematical modelling, data science, and biostatistics, aiding biotech and pharma companies in drug development. They use advanced computational tools and proprietary technology to optimize research design and decision-making across various stages of drug development. Their clientele includes prominent companies like Merck KGaA and Astellas.
YTD Price Performance: -48.00%
Average Trading Volume: 4,384,680
Technical Sentiment Signal: Buy
Current Market Cap: £1.2M
For detailed information about PYC stock, go to TipRanks’ Stock Analysis page.